Category - Markets

Roth Capital Partners launched coverage of Cyclacel Pharmaceuticals (NASDAQ:CYCC) with a “buy” rating and $8 price target. The stock closed at $1.57 on September 4. “We believe that Cyclacel, its clinical CDK inhibitor...

Analysts at BTIG and Ladenburg Thalmann initiated coverage of Vaccinex (NASDAQ:VCNX) with “buy” ratings and price targets of $20 and $22, respectively. The stock closed at $9.99 on August 31. Vaccinex, which went public...

H.C. Wainwright initiated coverage of Immune Design (NASDAQ:IMDZ) with a “buy” rating and $11 price target. The stock closed at $3.45 on August 29. “Based on our broad and long-term coverage of cancer immunotherapy, we...

H.C. Wainwright raised its price target for Sophiris Bio (NASDAQ:SPHS) to $10 from $4.30, citing autopsy results that found a patient deathin its Phase 2b trial for the treatment of localized prostate cancer was not...

H.C. Wainwright initiated coverage of Coherus BioSciences (NASDAQ:CHRS) with a “buy” rating and $28 price target. The stock closed at $19.75 on August 27. “We expect approval of UDENCYA, CHS-1701, in both the U.S. and...

Stifel upgraded Capital Senior Living (NYSE:CSU) to “hold” from “sell” but maintained its price target of $8.50, saying the shares have overshot its fair value estimates. The stock closed at $8.34 on August 23. “We...

Leerink initiated coverage of Neogenomics (NASDAQ:NEO) with an “outperform” rating and price target of $18. The stock closed at $12.84 on August 20. Analyst Puneet Souda writes that Neogenomics is a “uniquely positioned...

Roth Capital Partners downgraded Lannett Co. (NYSE AMER:LCI) to “neutral” and slashed its price target to $8 from $23 after the company lost an important customer and issued a profit warning. Near midday on August 20...

Needham initiated coverage of Liquidia Technologies (NASDAQ:LQDA) with a “buy” rating and $30 price target. The stock closed at $14.90 on August 17. Liquidia is developing LIQ861, a differentiated inhaled treatment for...

Ladenburg Thalmann initiated coverage of Achieve Life Sciences (NASDAQ:ACHV) with a “buy” rating and $12 price target. The stock finished at $2.80 on August 17. Achieve is developing cytisine, a natural compound with...